View all information regarding the medicines that are manufactured by Zydus Healthcare Ltd. including its generic drug name, trade name, how to use, the price, and its composition.

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Template formulary is a continually updated list of medications ... to improve glycemic control in adults with type 2 diabetes mellitus. Zydus Pharmaceuticals USA Inc President & CEO Punit ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

The US FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States.

Zydus is committed to unlocking new frontiers in neuroscience and developing transformative breakthrough medicines.” Also known as ZYIL1, Usnoflast has been explored in various pre-clinical ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

Global brokerage Nomura upgraded its rating on drugmaker Zydus Lifesciences to a 'buy' citing higher contribution from diabetes drug Sitagliptin. Accordingly, the firm also raised its price ...

Template formulary is a continually updated list of medications ... to improve glycemic control in adults with type 2 diabetes mellitus. Zydus Pharmaceuticals USA Inc President & CEO Punit ...